Clinical trials: Lymphomas,
B-cell Malignancy
Safety and Clinical Activity of ThisCART19 in Patients With r/r Non-Hodgkin's B Cell Lymphoma
A single arm, open-label, dose-escalation study to evaluate the safety and clinical activity of ThisCART19 (Allogeneic CAR-T targeting CD19) in patients with relapsed and/or refractory non-Hodgkin's B cell lymphoma (r/r B-NHL).
- Trial name
- NCT05106907
- Testing
- ThisCART19 cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fundamenta Therapeutics, Ltd.
Lymphoma, Non-Hodgkin
Study of Iodine-131 Anti-B1 Antibody for Patients With Non Hodgkin's Lymphoma Who Have Previously Received Rituximab
This is a single-arm, open-label, multicenter study of Iodine I-131 Anti B1 Antibody (Tositumomab and Iodine I 131 Tositumomab) for treatment of non-Hodgkin's lymphoma (NHL) who were previously treated with rituximab antibody.
- Trial name
- NCT00996593
- Testing
- Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab)
- Volunteers
- 43 people
- Sponsor
- GlaxoSmithKline
Leukemia-Lymphoma
Evaluation of ClearLLab Leukemia and Lymphoma Panels
Multi-center study of specimens from subjects presenting to the flow cytometry laboratory as part of their standard of care for hematological diseases work-up.
- Trial name
- NCT03413644
- Testing
- Flow Cytometry
- Where
- 4 sites in United States, Canada and 1 more
- Volunteers
- 482 people
- Sponsor
- Beckman Coulter, Inc.
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic Malignancies
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of SHC014748M in patients with relapsed or refractory indolent B-cell hematologic malignancies.
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), B-Cell Non-Hodgkin Lymphomas(NHL)
- Trial name
- NCT03588598
- Testing
- SHC014748M
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
Leukemia, B-Cell
Safety Study to Assess AFM11 in Patients With Relapsed or Refractory Adult B-precursor ALL
The purpose of the study is to determine the maximum tolerated dose (MTD) in patients with acute lymphoblastic leukemia (ALL) and to determine the safety and tolerability of increasing doses and different infusion times of AFM11…
- Trial name
- NCT02848911
- Testing
- AFM11
- Where
- 12 sites in Austria, Czechia and 3 more
- Volunteers
- 17 people
- Sponsor
- Affimed GmbH
Relapsed or Refractory Diffuse Large B-cell Lymphoma
Study of BEBT-908 in the Relapsed or Refractory Diffuse Large B-cell Lymphoma Subjects
This is an open,single-arm,multicenter phase II clinical study to evaluate the efficacy and safety of BEBT-908 for injection in the treatment of relapsed or refractory diffuse large B-cell lymphoma.
- Trial name
- NCT06074107
- Testing
- BEBT-908 for injection
- Where
- China
- Volunteers
- 128 people
- Sponsor
- BeBetter Med Inc
Advanced Hodgkin's Lymphoma
Procarbazine Hydrochloride Capsule (Natulan®) Clinical Trial Protocol
1. To observe and compare the overall response rate (ORR) of baseline BEACOPP and ABVD regimens for patients with advanced Hodgkin's lymphoma. 2.
- Trial name
- NCT02800447
- Testing
- Natulan, ABVD
- Volunteers
- 92 people
- Sponsor
- Lee's Pharmaceutical Limited
Alzheimer Disease, Dementia Alzheimers
A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease
The main purpose of this study is to evaluate safety, tolerability and immunogenicity of the vaccine ALZ-101 against Alzheimer's Disease. Patients diagnosed with early Alzheimer's will be included. The study have two parts.
- Conditions
- Alzheimer Disease, Dementia Alzheimers, Dementia, Mild
- Trial name
- NCT05328115
- Testing
- ALZ-101
- Where
- Finland
- Volunteers
- 33 people
- Sponsor
- Alzinova AB
Tumor or Lymphoma
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or Lymphoma
The purpose of this study is to evaluate the safety, pharmacokinetics (study of what the body does to a drug), and pharmacodynamics (study of what a drug does to the body) of JNJ-42756493, a pan-fibroblast growth factor receptor…
- Trial name
- NCT01703481
- Testing
- JNJ-42756493: Part 1, JNJ-42756493: Part 2, JNJ-42756493: Part 3
- Where
- 37 sites in United States, France and 1 more
- Volunteers
- 188 people
- Sponsor
- Janssen Research & Development, LLC
Secondary Immune Deficiency
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
This is a prospective, multicenter, open-label, single-arm study to assess the efficacy, safety, and pharmacokinetics (PK) of IgPro20 in adults with hematologic malignancies treated with B-cell targeting Chimeric antigen receptor…
- Trial name
- NCT07648264
- Testing
- IgPro20
- Where
- 60 sites in United States, Belgium and 9 more
- Volunteers
- 63 people
- Sponsor
- CSL Behring
Leukemia, Lymphoma, Chronic Lymphocytic, Leukemia, Prolymphocytic Leukemia, Small
A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Participants With Chronic Leukemia
This was a multicenter, Phase 1, standard 3+3 dose-escalation study to evaluate the safety and anti-neoplastic activity of moxetumomab pasudotox in relapsed or refractory participants with chronic lymphocytic leukemia (CLL)…
- Conditions
- Leukemia, Lymphoma, Chronic Lymphocytic, Leukemia, Prolymphocytic Leukemia, Small, Lymphocytic Lymphoma, Moxetumomab Pasudotox
- Trial name
- NCT00587457
- Testing
- CAT-8015 5 mcg/kg, CAT-8015 10 mcg/kg, CAT-8015 20 mcg/kg
- Where
- 3 sites in United States, Poland
- Volunteers
- 11 people
- Sponsor
- MedImmune LLC
Non-Hodgkin's Lymphoma
An Observational Study of First-Line Maintenance Rituximab (MabThera/Rituxan) in Participants With Follicular Non-Hodgkin's Lymphoma
This prospective observational study will evaluate the safety and efficacy of first-line rituximab maintenance therapy in participants with follicular non-Hodgkin's lymphoma.
- Trial name
- NCT01684865
- Testing
- Rituximab
- Where
- North Macedonia
- Volunteers
- 22 people
- Sponsor
- Hoffmann-La Roche
Lymphoma
Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma
This is a phase 1, multi-center, single-arm, open-label study evaluating the safety and anti-lymphoma activity of an autologous T cell product (ACTR707) in combination with rituximab in subjects with refractory or relapsed CD20+…
- Trial name
- NCT03189836
- Testing
- ACTR707, rituximab
- Where
- 11 sites in United States
- Volunteers
- 26 people
- Sponsor
- Cogent Biosciences, Inc.
Ulcerative Colitis
Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis
Phase 2 induction study with a long-term extension (LTE) period in participants with moderate to severe ulcerative colitis (UC).
- Trial name
- NCT05785715
- Testing
- NX-13 250mg, NX-13 750mg
- Where
- 35 sites in United States, Belgium and 2 more
- Volunteers
- 81 people
- Sponsor
- AbbVie
Follicular Lymphoma
Dose Optimization Study of Idelalisib in Follicular Lymphoma
The primary objective of this study is to establish a safe and effective dosing regimen of idelalisib in participants with relapsed or refractory follicular lymphoma (FL) who have no other therapeutic options.
- Trial name
- NCT02536300
- Testing
- Idelalisib
- Where
- 66 sites in Australia, Canada and 8 more
- Volunteers
- 96 people
- Sponsor
- Gilead Sciences
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
The purpose of this study is to investigate the efficacy and safety of BGB-16673 compared with investigator's choice (bendamustine plus rituximab or high-dose methylprednisolone plus rituximab or chlorambucil plus obinutuzumab)…
- Trial name
- CaDAnCe-303 (NCT06970743)
- Testing
- BGB-16673, Bendamustine, Rituximab
- Where
- 56 sites in China, Taiwan
- Volunteers
- 153 people
- Sponsor
- BeOne Medicines
Lymphoma
A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma
The purpose of this study is to assess the objective response rate of parsaclisib treatment in participants with relapsed or refractory follicular lymphoma.
- Trial name
- CITADEL-203 (NCT03126019)
- Testing
- Parsaclisib
- Where
- 83 sites in United States, Australia and 11 more
- Volunteers
- 126 people
- Sponsor
- Incyte Corporation
Peripheral T-cell Lymphoma
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
The purpose of this study is to evaluate the activity of romidepsin in patients with progressive or relapsed peripheral T-cell lymphoma (PTCL) who have already been treated with systemic therapy.
- Trial name
- NCT00426764
- Testing
- Romidepsin
- Where
- 90 sites in United States, Australia and 8 more
- Volunteers
- 131 people
- Sponsor
- Celgene
Primary Liver Cancer, SCLC
A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection
This is a study to evaluate the safety of MRX34 in patients with primary liver cancer or other selected solid tumors or hematologic malignancies. The drug is given intravenously, for 5 days in a row and then two weeks off.
- Conditions
- Primary Liver Cancer, SCLC, Lymphoma, Melanoma
- Trial name
- NCT01829971
- Testing
- MRX34
- Where
- 10 sites in United States, South Korea
- Volunteers
- 155 people
- Sponsor
- Mirna Therapeutics, Inc.
Mantle Cell Lymphoma
Safety Study to Evaluate Induction and Consolidation Treatment in Patients With Mantle Cell Lymphoma (LCM-04-02)
Mantle Cell Lymphoma (MCL) is a malignancy with a poor response to treatment and with a median survival of 2- 4 years since diagnosis.
- Trial name
- LCM-04-02 (NCT00505232)
- Testing
- Y-90 Ibritumomab tiuxetan
- Where
- 16 sites in Spain
- Volunteers
- 30 people
- Sponsor
- CABYC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.